Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASH 2024 CLL Highlights
23 January 2025 | Virtual Webinar
Post-ASH 2024 CLL Highlights
Featuring presentations & discussions on selected CLL abstracts from the 66th ASH Annual Meeting and Exposition
Thursday 23 January | 11:00 – 13:00 CST/ 17:00 – 19:00 GMT/ 18:00 – 20:00 CET
Chair: Barbara Eichhorst | Moderators: Matthew Davids and Kerry Rogers
The Post-ASH 2024 CLL Highlights was supported by Abbvie, Genentech and Lilly. Supporters have no influence over the production of content.
Explore all presentations and panel discussions below:
Session 1: MRD with novel treatment combinations
MRD-adapted duration of frontline venetoclax & obinutuzumab treatment for fit patients with CLL
Meghan Thompson Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Sonrotoclax and zanubrutinib as frontline treatment for CLL: BGB-11417-101 study
Jacob Soumerai Massachusetts General Hospital, Boston, MA, United States
Phase II CAPTIVATE study updates: fixed-duration ibrutinib + venetoclax for CLL/SLL
William Wierda The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Panel discussion
Session 2: Advances with BTK inhibitors and degraders
BRUIN CLL-321: pirtobrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated CLL/SLL
Jeff Sharman Willamette Valley Cancer Institute and Research Center, Eugene, OR, United States
Combined pirtobrutinib, venetoclax, and obinutuzumab as first-line treatment of patients with CLL
Nitin Jain The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Phase II study of AVO regimen in previously untreated patients with CLL enriched for high-risk disease
Matthew Davids Dana-Farber Cancer Institute, Boston, MA, United States
Interim analysis of the Phase III AMPLIFY trial
Jennifer Brown Dana-Farber Cancer Institute, Boston, MA, United States
Five-year follow-up of cohort 1 from the SEQUOIA study
Mazyar Shadman Fred Hutchinson Cancer Research Center, Seattle, WA, United States
Efficacy and safety of the BTK degrader NX-5948 in patients with R/R CLL
Nirav Niranjan Shah Medical College of Wisconsin, Milwaukee, WI, United States
CaDAnCe-101 study: preliminary efficacy and safety of the BTK degrader BGB-16673 in patients with R/R CLL/SLL
Meghan Thompson Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Panel discussion
Session 3: Advances with bispecifics and CAR T-cell therapies
Epcoritamab monotherapy in patients with R/R CLL: CLL expansion and optimization cohorts of EPCORE CLL-1
Alexey Danilov City of Hope, Duarte, CA, United States
Liso-cel combined with ibrutinib for patients with R/R CLL/SLL: primary results from TRANSCEND-CLL-004
William Wierda The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Panel discussion
Session 4: Assessing RWE, quality of life & outcomes in elderly & frail patients
QoL in patients with R/R CLL improves after MRD-guided treatment with ibrutinib plus venetoclax
Laura Eurelings Albert Schweitzer Hospital, Dordrecht, Netherlands
GAIA/CLL13 analysis: patient-reported QoL outcomes with venetoclax-based first-line combinations in CLL
Moritz Fürstenau University of Cologne, Cologne, Germany
First-line ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab in elderly or comorbid patients with CLL
Carsten Niemann Copenhagen University Hospital, Copenhagen, Denmark
CLL-Frail trial: acalabrutinib treatment in very old (>80y) and/or frail patients with CLL
Florian Simon University Hospital Cologne, Cologne, Germany
Association between dose reduction & duration of therapy in patients receiving ibrutinib or acalabrutinib for CLL
Mazyar Shadman Fred Hutchinson Cancer Research Center, Seattle, WA, United States
Panel discussion
